CJC-1295 (No DAC) 2 mg – GHRH Analogue – Short

Sale!
CJC-1295 (No DAC) 2 mg - GHRH Analogue - Short

CJC-1295 (No DAC) 2 mg – GHRH Analogue – Short

Original price was: R849,99.Current price is: R679,99.

CJC-1295 without DAC, also known as Modified GRF (1–29) or Mod-GRF, is a short-acting Growth Hormone–Releasing Hormone (GHRH) analogue designed to stimulate natural, pulsatile growth hormone (GH) release. Unlike CJC-1295 with DAC, which binds albumin for prolonged activity, the No-DAC variant is optimized for rapid onset and short duration, making it ideal for modelling physiological GH pulses rather than sustained elevations.

In research settings, CJC No DAC is used for GH pulse-timing studies, sleep-cycle GH response modelling, body-composition signaling, synergy experiments with growth hormone secretagogues (GHS) such as Ipamorelin, and rapid GH/IGF-1 response mapping. This 2 mg cartridge is configured specifically for The Clinic 2 mL / 200-click pen system to standardize dosing.

Dosage Protocol — Pen System

The Clinic standardises all cartridges to simplify research use and dose reproducibility.

  • Pen volume: 2 mL
  • Total clicks per pen: 200 clicks
  • CJC-1295 No DAC content per cartridge: 2 mg (2,000 mcg)
  • Strength: 2 mg ÷ 200 clicks = 0.01 mg (10 mcg) per click
  • Reference points: 10 clicks = 100 mcg, 20 clicks = 200 mcg, 30 clicks = 300 mcg, 40 clicks = 400 mcg

This configuration meets The Clinic requirement of a minimum mid-point dose of at least 10 clicks.

Categories: , , Tags: , , , Brand:

Description

Mechanism of Action
CJC-1295 No DAC acts as a selective GHRH receptor agonist. By binding to GHRH receptors on somatotroph cells in the anterior pituitary, it triggers short bursts of endogenous GH secretion that closely mimic natural secretory spikes. The Modified GRF (1–29) structure is engineered to resist rapid enzymatic degradation, providing a functional window typically in the 30–60 minute range.Pulsatile GH output driven by CJC No DAC results in proportional increases in IGF-1, while preserving the normal on/off rhythm of GH signaling. Research explores its use in GH-axis mapping, sleep-anchored GH secretion, body-composition signaling and recovery-focused models.

Key Themes

  • Enhanced pulsatile GH signaling in short-acting GHRH models.
  • IGF-1 elevation aligned with physiologic endocrine patterns.
  • Sleep and circadian GH-response investigations.
  • Synergistic GH amplification when combined with ghrelin agonists such as Ipamorelin.
  • Body-composition, recovery and metabolic-pathway research frameworks.

Suggested Research Dosing – Daily Pulsatile Model

Phase Reference Dose (mcg) Clicks per Event Notes
Baseline (Weeks 1–2) 100–150 mcg 10–15 clicks GH-axis mapping and IGF-1 baseline response
Standard Phase (Weeks 3–6) 200 mcg 20 clicks Core pulsatile GH modelling
High-Pulse Arm (Weeks 7–10) 300 mcg 30 clicks Increased GH peak amplitude comparison

Synergy Model – Combined with GHS (e.g. Ipamorelin)

Timing Reference Dose (mcg) Clicks per Event Notes
Pre-Sleep 200–300 mcg 20–30 clicks Aligns with endogenous nocturnal GH spike
Optional AM Pulse 100–200 mcg 10–20 clicks Used in dual-pulse endocrine mapping with GHS overlays

All dosing values above are illustrative  examples only and must be tailored to the specific model, approvals and study design. They are not prescribing guidance.

Frequency & Cycle Length

  • Frequency: Typically 1–2 events per day, often around sleep or fasting windows.
  • Cycle length: GH-axis and sleep studies often run 4–8 weeks; body-composition/metabolic models 8–12 weeks.

Expected Outcomes

In laboratory and model systems, CJC-1295 No DAC exposure has been associated with:

  • Increased pulsatile GH amplitude and frequency.
  • IGF-1 elevations consistent with physiologic endocrine patterns.
  • Improved slow-wave sleep endocrine alignment in sleep-focused models.
  • Exploratory data on lean mass signalling and fat-oxidation pathways.
  • Enhanced GH response in combination protocols with ghrelin agonists such as Ipamorelin.

These findings are research observations only and must not be interpreted as guaranteed or therapeutic outcomes.

Product Details & Cartridge Summary

Product Information

  • Compound: CJC-1295 (No DAC) / Modified GRF (1–29)
  • Content: 2 mg CJC-1295 No DAC per 2 mL cartridge
  • Form: Pre-reconstituted research peptide solution

What’s in the Box

  • 1 × CJC-1295 No DAC 2 mg cartridge (Clinic pen compatible)
  • 1 × replacement needle

Related Products

Related products